Both Scenarios Are Possible—But Echocardiography Likely Overestimated the Initial LVEF
The decline from 53% to 40% most likely reflects echocardiographic overestimation rather than true disease progression, as cardiac MRI is the reference standard and consistently measures lower LVEF values than echocardiography. However, you cannot definitively exclude worsening heart failure without additional clinical context.
Understanding the Measurement Discrepancy
CMR vs. Echocardiography: Expected Differences
The observed 13-percentage-point difference falls within the well-documented range of inter-modality variability:
- Echocardiography systematically overestimates LVEF compared to CMR by an average of 6-7 percentage points 1, 2
- In real-world clinical practice, only 64.4% of patients have their LVEF category confirmed by both modalities 2
- CMR upwardly reclassifies 28-35% of patients when using standard heart failure classifications 3, 2, 4
- The correlation between modalities is only moderate (r = 0.49-0.66), with substantial variation even in core laboratory settings 5
Why Echocardiography Overestimates
Echocardiography underestimates both end-diastolic and end-systolic volumes (by approximately 70 mL each), which mathematically inflates the calculated ejection fraction 1. This is particularly problematic in patients with:
- Wall motion abnormalities (septal or lateral)—these are strong predictors of misclassification (odds ratio 1.82-2.02) 4
- Dilated ventricles
- Poor acoustic windows
Clinical Decision Algorithm
Step 1: Assess for True Disease Progression
Look for these indicators that suggest actual worsening:
- New or worsening symptoms: dyspnea, orthopnea, edema, exercise intolerance
- Elevated natriuretic peptides (BNP/NT-proBNP) compared to prior values
- Medication non-adherence or recent withdrawal of guideline-directed medical therapy (GDMT)
- New cardiac stressors: myocardial infarction, arrhythmias (especially atrial fibrillation), uncontrolled hypertension, cardiotoxic exposures
- Interval between studies: If months have passed with known progressive disease (e.g., untreated ischemic cardiomyopathy)
Step 2: Reclassify Based on CMR
Accept the CMR value of 40% as the accurate measurement 3, 1. This patient now has:
- HFrEF (LVEF ≤40%) per 2022 AHA/ACC/HFSA guidelines 6
- This reclassification has major therapeutic implications for device therapy eligibility (ICD/CRT) and medication intensification
Step 3: Recognize the Trajectory Matters
The 2022 AHA/ACC/HFSA guidelines emphasize that "trajectory of LVEF can be important, and a significant reduction in LVEF over time is a poor prognostic factor" 6. However, this assumes both measurements are accurate. In your case:
- If the initial echo was 53% but CMR would have shown ~46% (accounting for typical 6-7% overestimation), then the true decline is only 6 percentage points
- This modest decline over months may represent measurement variability rather than disease progression
Common Pitfalls to Avoid
Do not assume the echocardiogram was accurate simply because it was performed first—CMR is the reference standard 3, 1
Do not repeat echocardiography to "confirm" the CMR finding—this adds no value and may cause confusion. The CMR is already your most accurate measurement.
Do not delay treatment intensification if the patient now meets criteria for HFrEF therapies based on LVEF ≤40%. Most clinical trials establishing LVEF thresholds used echocardiography, so CMR-based LVEF of 40% may actually represent more severe dysfunction than the trial populations 1, 2.
Consider that 42.3% of patients with severely impaired LVEF by echo are upwardly reclassified by CMR 2—but your patient went the opposite direction, making true progression more plausible if clinical deterioration is present.
Practical Recommendation
Treat this as HFrEF with LVEF 40% and optimize GDMT immediately (ACE-I/ARB/ARNI, beta-blocker, MRA, SGLT2i) 6. If the patient has clinical signs of worsening (symptoms, elevated natriuretics, medication non-adherence), this represents true progression requiring aggressive management. If the patient is clinically stable, the CMR simply provided a more accurate baseline measurement, revealing that the initial echo overestimated function—a scenario occurring in approximately one-third of patients 2, 4.